Jingfeng Luo
Overview
Explore the profile of Jingfeng Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu X, Yuan S, Zhou S, Sun T, Wang C, Ying S, et al.
Int J Biol Sci
. 2023 Aug;
19(12):3694-3708.
PMID: 37564210
Golgi-protein 73 (GP73) is highly expressed in hepatocellular carcinoma (HCC) and, as a secretory protein, it has been proposed as a serum biomarker indicating progression of HCC. The underlying mechanism...
2.
Zhu L, Zhu Y, Li F, Meng Y, Wang H, Xu W, et al.
Clin Transl Med
. 2023 Jul;
13(7):e1337.
PMID: 37477089
Background: Energy balance has long been known to extend lifespans and inhibit carcinogenesis in multiple species by slowing age-related epigenetic changes while the underlying mechanisms remain largely unknown. Herein, we...
3.
Miao Y, Xie F, Cen J, Zhou F, Tao X, Luo J, et al.
ACS Macro Lett
. 2022 May;
7(6):693-698.
PMID: 35632979
α-Amino acid -thiocarboxyanhydrides (NTAs) are promising cyclic monomers to synthesize polypeptides and polypeptoids via controlled ring-opening polymerizations. Superior to -carboxyanhydrides requiring protection on hydroxyl groups, NTAs are able to tolerate...
4.
Dong X, Luo J, Lan P, Guo X, Zhao X, Wang X, et al.
Eur Radiol
. 2021 Jan;
31(7):4615-4624.
PMID: 33409796
Objectives: To develop a nanoparticle-based MRI protocol based on transrectal administration of intestine-absorbable nanoparticle contrast agents to evaluate ulcerative colitis (UC). Methods: Solid lipid nanoparticles (SLNs) were synthesized by loading...
5.
Jiang S, Zhou F, Zhang Y, Zhou W, Zhu L, Zhang M, et al.
J Cancer
. 2020 Apr;
11(12):3623-3633.
PMID: 32284759
Osteosarcoma is the most common primary malignant tumor of bone. Tumorigenic investigation of osteosarcoma cell lines may facilitate preclinical studies of targeted therapy. Therefore, the aim of this study was...
6.
Luo Y, Luo J, Peng H
Genet Test Mol Biomarkers
. 2019 Sep;
23(9):644-651.
PMID: 31524543
To investigate the association between polymorphisms in the rs2010963 and rs69947 loci of the vascular endothelial growth factor A () gene; the rs4646994 locus of the angiotensin I converting enzyme...
7.
Zhang Y, Luo J, Dong X, Yang F, Zhang M, Zhao J, et al.
Ann Surg Oncol
. 2019 Jul;
26(12):4134-4147.
PMID: 31359275
Background: Cholangiocarcinoma (CCA) is a rare, aggressive and highly lethal tumor. The disease is very difficult to diagnose and multi-modality treatments are ineffective. To improve our understanding of the biological...
8.
Luo J, Zhou Y, Chen Q, Zhao X, Zhang M
Cell Reprogram
. 2019 Jun;
20(6):365-370.
PMID: 31251671
Embryonic stem cells (ESCs) are characterized by their ability to self-renew and their potential to differentiate into any cell type. Therefore, identification of novel molecular markers to verify the pluripotent...
9.
Luo J, Zhou J, Xie F, Zhu Y, Zhou F, Zhang S, et al.
Am J Cancer Res
. 2018 Sep;
8(8):1595-1603.
PMID: 30210927
Cholangiocarcinoma is a most lethal malignancy frequently resistant to chemotherapy. Herpes simplex virus thymidine kinase/Ganciclovir (HSV-TK/GCV) suicide gene therapy is a promising approach to treat different cancers, including cholangiocarcinoma. However...
10.
Zhou F, Zhang Y, Xu X, Luo J, Yang F, Wang L, et al.
Cancer Cell Int
. 2018 Aug;
18:118.
PMID: 30140169
Background: Basal/human epidermal growth factor receptor (HER)2-positive (HER2+) breast cancer is resistant to monoclonal antibody (herceptin) treatment. There are currently only three basal/HER2+ breast cancer cell lines available, but they...